Chen Zhongxiu, Li Chen, Lin Ke, Zhang Qing, Chen Yucheng, Rao Li
Department of Cardiology, West China Hospital of Sichuan University, Chengdu-China.
Anatol J Cardiol. 2018 Feb;19(2):140-147. doi: 10.14744/AnatolJCardiol.2017.8124.
Traditional circulating biomarkers play a fundamental role in the diagnosis and prognosis of acute myocardial infarction (AMI). However, they have several limitations. microRNAs (miRs), a class of RNA molecules that do not encode proteins, function directly at the RNA level by inhibiting the translation of messenger RNAs. Due to their significant roles in disease development, they can be used as biomarkers. Accumulating evidence has revealed an attractive role of miRs as biomarkers of AMI and its associated symptoms, including vulnerable atherosclerotic plaques, and their role in disease diagnosis, platelet activation monitoring, and prognostic outcome prediction. This manuscript will highlight the recent updates regarding the involvement of miRs as biomarkers in AMI and emphasize their value in vulnerable atherosclerotic plaque prediction and monitoring of platelet activation.
传统的循环生物标志物在急性心肌梗死（AMI）的诊断和预后中起着重要作用。然而，它们存在一些局限性。微小RNA（miRs）是一类不编码蛋白质的RNA分子，通过抑制信使RNA的翻译在RNA水平直接发挥作用。由于它们在疾病发展中具有重要作用，因此可作为生物标志物。越来越多的证据表明，miRs作为AMI及其相关症状（包括易损动脉粥样硬化斑块）的生物标志物具有重要作用，以及它们在疾病诊断、血小板活化监测和预后结果预测中的作用。本文将重点介绍miRs作为AMI生物标志物的最新研究进展，并强调它们在易损动脉粥样硬化斑块预测和血小板活化监测中的价值。
